Compounded Semaglutide Dosing and Protocols: A Complete Clinical Reference

Published Jun 2, 2026Updated Jun 2, 2026Last reviewed Jun 2, 2026

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last updated: May 2026

Last October, a 42-year-old patient named Rachel in Phoenix called her prescribing clinic in a panic. She'd been on compounded semaglutide for six weeks, and a friend had texted her a Reddit screenshot showing "the correct dose" at week six was 1.0 mg. Rachel's clinician had her at 0.5 mg. She'd already drawn up what she thought was 1.0 mg from her vial, a 2.5 mg/mL preparation, using a unit conversion she found on a forum. "I pulled up 40 units because the chart said 40 units for 1.0 mg," she told the nurse on the phone. The problem: that chart was for a 2.5 mg/mL vial, and Rachel's pharmacy had switched her to a 5 mg/mL concentration. She was about to inject twice her intended dose. The nurse caught it in time. Not everyone is that lucky.

This page exists because of patients like Rachel. Semaglutide dosing is the most misunderstood part of GLP-1 therapy, and the confusion isn't trivial. It leads to ER visits, to premature discontinuation, and to patients who give up on a medication that would have worked if the titration had been managed properly.

Here's what this guide covers: the published Wegovy escalation schedule that serves as the reference standard, how compounded semaglutide protocols relate to that schedule, the unit-versus-milligram problem that trips people up, and the clinical logic behind dose holds, restarts, and maintenance. It's a reference document, not a prescription, and it should not be used to self-titrate.

Compounded semaglutide is not FDA-approved. Dosing for compounded preparations is determined by the prescribing clinician based on patient-specific factors, informed by (but not identical to) the titration schedule used in the trials that supported approval of Wegovy and Ozempic. The doses cited here reference the published Wegovy escalation schedule, the Ozempic escalation schedule, and dose-response data from SUSTAIN, STEP-1, STEP-3, and STEP-4.

For context on what compounded semaglutide is, how 503A and 503B pharmacies prepare it, and the legal framework that governs its dispensing, see the pillar guide on compounded semaglutide.

The Wegovy Titration Schedule (and Why It's Five Steps, Not One)

The FDA-approved Wegovy titration schedule is the reference point against which most compounded semaglutide protocols are written. It exists for one reason: your gut needs time to adjust. That's it. The slow ramp is the tolerability strategy.

Five steps over sixteen weeks:

Weeks 1 through 4: 0.25 mg once weekly
Weeks 5 through 8: 0.5 mg once weekly
Weeks 9 through 12: 1.0 mg once weekly
Weeks 13 through 16: 1.7 mg once weekly
Week 17 onward: 2.4 mg once weekly (maintenance)

A critical point that most patients miss: the 0.25 mg starting dose is not a therapeutic dose. It's a tolerability dose. It's the pharmaceutical equivalent of wading into the shallow end. The slow gastric emptying effect that causes most GI side effects needs to develop gradually rather than hitting all at once. Patients who start at 0.25 mg and wonder why they're not losing weight at week two are measuring the wrong thing. The weight loss comes later.

The full clinical effect on weight was established at 2.4 mg in STEP-1, where patients lost a mean of 14.9 percent of body weight over 68 weeks compared to 2.4 percent on placebo (Wilding et al., NEJM 2021). That's the number everyone sees. What they don't see is the sixteen weeks of careful escalation it took to get patients there without half of them quitting from nausea.

How Ozempic's Schedule Differs (and Why It Matters for Weight Loss)

Ozempic was approved for type 2 diabetes, not weight management. Different goal, different escalation, lower ceiling:

Weeks 1 through 4: 0.25 mg once weekly
Weeks 5 through 8: 0.5 mg once weekly
Week 9 onward: 1.0 mg once weekly, with possible escalation to 2.0 mg

The 2.0 mg dose was added after the SUSTAIN-FORTE trial showed additional A1c reduction. But Ozempic was never designed to push to the 2.4 mg weight-management dose. This is the boring truth behind a lot of disappointing results: patients prescribed Ozempic off-label for weight loss hit a ceiling around 1.0 to 2.0 mg and wonder why their numbers don't match the headlines. The headlines are about the 2.4 mg Wegovy dose. The math doesn't lie.

Compounded Protocols: Close to Wegovy, Not Identical

Compounded semaglutide is dispensed by a 503A pharmacy or a 503B outsourcing facility under an individual prescription. The prescribing clinician sets the dose, the titration interval, and the concentration. There is no single standardized compounded protocol because compounded preparations are, by definition, patient-specific.

That said, most clinically sound compounded protocols hew close to the Wegovy escalation curve. Same five-step titration, same sixteen-week ramp. The difference is flexibility. A prescribing clinician can pause or extend any step if the patient is dealing with persistent nausea, has already lost adequate weight at a lower dose, or has clinical reasons to go slower.

Some clinicians stretch each step to five or six weeks rather than four, especially in patients with a history of GI sensitivity, gastroparesis risk factors, or lower baseline BMI. This slower approach tends to produce better adherence. GI side effects are the leading cause of GLP-1 discontinuation in the published literature, and keeping patients on the medication matters more than racing to the top dose.

For a deeper look at how 503A and 503B compounding works, see our supporting article on 503A versus 503B pharmacies.

The Unit-vs.-Milligram Problem That Sends People to the ER

This is the section I wish didn't need to exist. But it does.

Semaglutide is dosed in milligrams. Insulin syringes are calibrated in units, where 1 unit equals 0.01 mL on a standard U-100 syringe. The milligram dose translates to a different number of units depending on the concentration of your vial.

Think of it like this: if you're making a cocktail and the recipe calls for two ounces of whiskey, the number of seconds you pour depends on how fast the bottle pours. Different bottle, different pour time, same amount of whiskey. Different concentration vial, different number of units on the syringe, same milligram dose.

A 2.5 mg/mL vial and a 5 mg/mL vial require different syringe volumes to deliver the same dose. The pharmacy calculates this and puts the correct number of units on your prescription label and dosing instructions. Patients should never calculate their own dose from a Reddit chart or a friend's vial. Concentrations vary between pharmacies and sometimes between batches from the same pharmacy.

If your vial label and your dosing instructions don't match, do not inject. Call your prescribing clinic. This is not an area where "close enough" is acceptable.

For the detailed breakdown, see our article on semaglutide units versus milligrams.

Missed Doses, Restarts, and the Tolerance Problem

The Wegovy and Ozempic prescribing information includes specific guidance for missed doses, and most compounded protocols mirror it:

If you miss one dose: Take it as soon as you remember, as long as your next scheduled dose is more than 48 hours away. If it's less than 48 hours, skip the missed dose and take the next one on schedule. Never double up.

If you miss two or more consecutive doses: This is where things get clinically important. The Wegovy label recommends restarting at the most recent tolerated dose for one cycle before resuming titration. A patient at 1.7 mg who misses three weeks would typically restart at 1.0 mg for four weeks before stepping back up.

Here's the thing most patients don't realize: the slow gastric emptying effect that makes the drug tolerable declines within days of stopping. Your GI tract de-adapts fast. A full-dose restart in a patient who has lost tolerance is the leading cause of severe nausea and emergency department visits. The restart protocol isn't bureaucratic caution. It's based on how the drug actually works in the body.

For more on this, see our article on restarting semaglutide after a break.

Dose Holds, Reductions, and the Case for Staying Put

A dose hold means keeping a patient at their current dose for an extra cycle rather than escalating on schedule. It's a clinical decision, not a failure. Dose holds make sense when:

Persistent moderate to severe nausea, vomiting, or diarrhea hasn't resolved
The patient is losing weight adequately at the current dose and doesn't need more appetite suppression
The patient is approaching goal weight and the clinician is preparing for a maintenance phase
A recent medication change or new medical condition warrants stability

Dose reductions, stepping back to a previous dose, are the alternative to quitting when side effects become intolerable. In the published trials, approximately 7 percent of Wegovy patients discontinued due to GI adverse events (Wilding et al., NEJM 2021). In clinical practice, a dose reduction with extended titration is often enough to keep patients on therapy who would otherwise stop entirely.

My genuinely held opinion: the pressure to push to 2.4 mg as fast as possible, whether from patient expectations or clinic protocols optimized for speed, is the single biggest prescribing error in GLP-1 therapy right now. Slower is almost always better. The patients who stay on the medication are the patients who lose the weight.

For a complete breakdown of the side effect profile, see our cluster hub on semaglutide side effects and safety.

What Each Dose Actually Delivers: The Trial Data

The dose-response relationship is well characterized. Here's what the major trials showed:

At 2.4 mg (the Wegovy maintenance dose):

STEP-1: 14.9 percent mean body weight loss over 68 weeks (Wilding et al., NEJM 2021)
STEP-3 (2.4 mg plus intensive behavioral therapy): 16.0 percent (Wadden et al., JAMA 2021)
STEP-4 (continuation vs. withdrawal): patients who continued 2.4 mg for an additional 48 weeks lost an additional 7.9 percent; patients switched to placebo regained 6.9 percent (Rubino et al., JAMA 2021)

At 1.0 mg (the Ozempic diabetes dose):

SUSTAIN trials showed weight loss in the range of 4 to 6 percent in type 2 diabetes patients (Sorli et al., Lancet Diabetes Endocrinol 2017; Ahrén et al., Lancet Diabetes Endocrinol 2017)

The takeaway is blunt: patients on compounded protocols that target lower, diabetes-style doses should not expect the same weight outcomes as patients on the full 2.4 mg weight-management dose. The dose you're prescribed determines the result you can reasonably expect. There's no shortcut around this.

But "lower dose equals less weight loss" doesn't mean everyone needs 2.4 mg. Many patients achieve excellent outcomes at 1.7 mg and never need to push higher. The conversation with your prescribing clinician about target dose and realistic expectations is one of the most important ones you'll have.

Maintenance Dosing: What Happens After You Hit Your Goal

Maintenance dosing is where the evidence gets thinner and the opinions get louder.

The best published data comes from STEP-4 (Rubino et al., JAMA 2021), which compared continuation of 2.4 mg to placebo after a 20-week run-in. The message was unambiguous: stop the drug, regain the weight. The weight regain is biologically driven. It is not a function of willpower or discipline.

Most clinically reasonable maintenance protocols hold the patient at the dose where they achieved their goal weight. Reached goal at 1.7 mg? Maintenance is 1.7 mg. Reached goal at 2.4 mg? Maintenance is 2.4 mg, though some clinicians step down to 1.7 mg after a period of documented weight stability.

Lower-dose maintenance (0.5 mg or 1.0 mg, sometimes every other week) is used by some clinicians in patients who want to minimize cost and side effects after reaching goal. This is off-label, the evidence base is limited, and the risk is straightforward: weight regain. It should be a shared decision between patient and clinician, not a cost-cutting measure taken unilaterally.

For more on maintenance, see our cluster hub on long-term and maintenance.

Injection Basics: Site Rotation, Storage, Timing

Semaglutide is a subcutaneous injection, once weekly. Approved sites:

Abdomen (at least two inches from the navel)
Front of the thigh
Back of the upper arm

Rotate between sites to reduce lipohypertrophy and injection-site reactions. The injection should be subcutaneous, not intramuscular. If you're hitting muscle, you're going too deep.

Timing: same day each week, but the time of day doesn't matter. Semaglutide has a half-life of approximately one week, so whether you inject at 7 a.m. or 10 p.m. is clinically irrelevant. Can be taken with or without food.

Storage: refrigerate between 36 and 46 degrees Fahrenheit. Once in use, most compounded preparations are stable at room temperature for up to 28 days, but check the beyond-use date on your specific vial's label. That date is pharmacy-specific and batch-specific. Don't use a vial past it.

For step-by-step injection technique, see our article on how to inject compounded semaglutide.

Special Populations: Kidneys, Liver, Diabetes Meds, and Pregnancy

The Wegovy label does not require dose adjustment for renal impairment, hepatic impairment, or age in the populations studied. Caution and slower titration are recommended in patients with severe renal disease, end-stage liver disease, or a history of pancreatitis. Compounded protocols typically follow the same framework.

Patients on insulin or sulfonylureas: Adding semaglutide increases hypoglycemia risk. The standard approach is to adjust the concurrent diabetes medication, not the semaglutide. This requires coordination with the patient's primary diabetes care team, not a solo decision by the weight-management clinician.

Pregnancy and breastfeeding: These are contraindications. Period. Semaglutide should be discontinued at least two months before a planned pregnancy due to its long half-life. Patients of childbearing potential should use reliable contraception during therapy.

This hub is part of the Compounded Semaglutide Dosing and Protocols cluster. Related supporting articles:

For the foundational overview of compounded semaglutide, return to the pillar guide.

Frequently Asked Questions

What are the standard Wegovy doses? The Wegovy escalation schedule uses five doses: 0.25 mg (weeks 1 through 4), 0.5 mg (weeks 5 through 8), 1.0 mg (weeks 9 through 12), 1.7 mg (weeks 13 through 16), and 2.4 mg (week 17 onward as the maintenance dose).

Can I skip the lower Wegovy doses and start at a higher dose? No. The titration exists for GI tolerability. Skipping doses dramatically increases the risk of severe nausea, vomiting, and discontinuation. The published trials titrated every patient through the full schedule.

Why is my compounded semaglutide dose different from my friend's at the same week? Compounded protocols are patient-specific. Your clinician may be using a slower titration based on your medical history, side effect profile, or weight-loss response. Different pharmacies also use different vial concentrations, which changes the syringe volume but not necessarily the milligram dose.

What should I do if I miss a dose of semaglutide? If your next dose is more than 48 hours away, take the missed dose as soon as you remember. If it's less than 48 hours until your next dose, skip the missed one and resume on schedule. Never double a dose. If you've missed two or more weeks, contact your prescribing clinician about a restart protocol.

How long do I have to stay on semaglutide? Current evidence from STEP-4 (Rubino et al., JAMA 2021) shows significant weight regain after discontinuation. Most obesity medicine specialists treat semaglutide as long-term therapy, similar to blood pressure or cholesterol medication. The decision to continue, reduce, or discontinue should be made with your clinician.

Is 1.0 mg semaglutide enough for weight loss? For some patients, yes. Weight loss at 1.0 mg is typically in the 4 to 6 percent range based on SUSTAIN trial data, compared to 14.9 percent at 2.4 mg in STEP-1. Whether that's "enough" depends on your goals and clinical situation.

Can I use the same dose chart for different compounded semaglutide vials? Absolutely not. Dose charts are concentration-specific. A chart for a 2.5 mg/mL vial will produce incorrect (potentially dangerous) doses if applied to a 5 mg/mL vial. Always use the dosing instructions that came with your specific prescription.

Not FDA-approved. HealthRX is not a medical practice. Information on this site is for educational purposes and is not a substitute for individualized medical advice. Treatment decisions are made between you and a licensed clinician. Compounded semaglutide is dispensed by state-licensed 503A pharmacies and FDA-registered 503B outsourcing facilities under individual prescriptions. References: SUSTAIN program (Sorli et al., Lancet Diabetes Endocrinol 2017; Ahrén et al., Lancet Diabetes Endocrinol 2017), STEP-1 (Wilding et al., NEJM 2021), STEP-3 (Wadden et al., JAMA 2021), STEP-4 (Rubino et al., JAMA 2021), SELECT (Lincoff et al., NEJM 2023).